VTGN - Gunggung utang perusahaan VistaGen Therapeutics Inc

Vistagen Therapeutics (VTGN) relies on the immense potential of the rapid-acting anxiety treatment market. The debt history visualizes the leverage, where the indicator is fixed at 0.00. Patents for nasal sprays ensure high future margins; however, the lack of sales makes the company dependent on clinical trial results, creating a certain degree of financial instability.

This indicator aggregates all short-term and long-term credit obligations, allowing for an assessment of the business's total debt load and the cost of servicing borrowed capital. The current value of 0.00, represented by the volume of borrowed funds, is critical for Vistagen Therapeutics, as financing non-cyclical developments in psychiatric pharmacology requires stable capital regardless of macroeconomic GDP fluctuations.